Three known risk factors, the presence of a MYCN amplification in the tumor, patient age > 18 months at diagnosis and stage 4 disease according to the International Neuroblastoma Staging System (INSS), significantly correlated with elevated MDM2 expression in tumors (Figure 1C-1E). Here, MDM2 is linked to neuroblastoma.